A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation

Journal of Thrombosis and Thrombolysis

Volumn 28, Issue 2, 2009, Pages 132-139

  Volovyk, Zoya ^a   Monroe, Dougald M ^b   Qi, YiWei ^c   Becker, Richard ^a   Hoffman, Maureane ^a,d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c Momenta Pharmaceuticals Inc   (United States)

^d DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Antithrombin; aPTT; Low molecular weight heparin; Thrombin; Unfractionated heparin

Indexed keywords

ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; M 118; PROTHROMBIN A; UNCLASSIFIED DRUG;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL;

ANTICOAGULANTS; BIOLOGICAL ASSAY; BLOOD PLATELETS; ENOXAPARIN; FACTOR XA; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MODELS, BIOLOGICAL; MONOCYTES; PARTIAL THROMBOPLASTIN TIME; THROMBIN;

EID: 67849114034     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-009-0360-0     Document Type: Article

References (42)

1. Conard J, Brosstad F, Lie Larsen M et al (1983) Molar antithrombin concentration in normal human plasma. Haemostasis 13:363-368
2. Bauer KA, Rosenberg RD (1991) Role of antithrombin III as a regulator of in vivo coagulation. Semin Hematol 28:10-18
3. Langdown J, Johnson DJ, Baglin TP et al (2004) Allosteric activation of antithrombin critically depends upon hinge region extension. J Biol Chem 279:47288-47297. doi: 10.1074/jbc.M408961200
4. Ye S, Cech AL, Belmares R et al (2001) The structure of a Michaelis serpin-protease complex. Nat Struct Biol 8:979-983. doi: 10.1038/ nsb1101-979
5. Kaslik G, Kardos J, Szabo E et al (1997) Effects of serpin binding on the target proteinase: Global stabilization, localized increased structural flexibility, and conserved hydrogen bonding at the active site. Biochemistry 36:5455-5464. doi: 10.1021/bi962931m
6. Huntington JA, Read RJ, Carrell RW (2000) Structure of a serpin-protease complex shows inhibition by deformation. Nature 407:923-926. doi: 10.1038/35038119
7. Skinner R, Abrahams JP, Whisstock JC et al (1997) The 2.6 A structure of antithrombin indicates a conformational change at the heparin binding site. J Mol Biol 266:601-609. doi: 10.1006/jmbi.1996.0798
8. Choay J, Petitou M, Lormeau JC et al (1983) Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 116:492-499
9. Olson ST, Bjork I, Sheffer R et al (1992) Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 267:12528-12538
10. Quinsey NS, Whisstock JC, Le Bonniec B et al (2002) Molecular determinants of the mechanism underlying acceleration of the interaction between antithrombin and factor Xa by heparin pentasaccharide. J Biol Chem 277:15971-15978. doi: 10.1074/jbc.M108131200
11. Chuang YJ, Swanson R, Raja SM et al (2001) Heparin enhances the specificity of antithrombin for thrombin and factor Xa independent of the reactive center loop sequence. Evidence for an exosite determinant of factor Xa specificity in heparin-activated antithrombin. J Biol Chem 276:14961-14971. doi: 10.1074/jbc.M011550200
12. Izaguirre G, Swanson R, Raja SM et al (2007) Mechanism by which exosites promote the inhibition of blood coagulation proteases by heparin-activated antithrombin. J Biol Chem 282:33609-33622. doi: 10.1074/jbc.M702462200
13. Danielsson A, Raub E, Lindahl U et al (1986) Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem 261:15467-15473
14. Rezaie AR (1998) Calcium enhances heparin catalysis of the antithrombin-factor Xa reaction by a template mechanism. Evidence that calcium alleviates Gla domain antagonism of heparin binding to factor Xa. J Biol Chem 273:16824-16827. doi: 10.1074/jbc.273.27.16824
15. Rosenberg RD, Armand G, Lam L (1978) Structure-function relationships of heparin species. Proc Natl Acad Sci USA 75:3065-3069. doi: 10.1073/ pnas.75.7.3065
16. Oosta GM, Gardner WT, Beeler DL et al (1981) Multiple functional domains of the heparin molecule. Proc Natl Acad Sci USA 78:829-833. doi: 10.1073/ pnas.78.2.829
17. Young E, Wells P, Holloway S et al (1994) Ex-vivo and in vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 71:300-304
18. Hirsh J, Warkentin TE, Shaughnessy SG et al (2001) Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119:64S-94S. doi: 10.1378/chest.119.1_suppl.64S
19. Bernardi E, Prandoni P (2005) Subcutaneous unfractionated heparin compared with low-molecular-weight heparin for the initial treatment of venous thromboembolism. Curr Opin Pulm Med 11:363-367. doi: 10.1097/ 01.mcp.0000174228.47725.79
20. Hull RD (2008) Treatment of pulmonary embolism: The use of low-molecular-weight heparin in the inpatient and outpatient settings. Thromb Haemost 99:502-510
21. Buller CE, Pate GE, Armstrong PW et al (2006) Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment. Can J Cardiol 22:511-515
22. Sundaram M, Qi Y, Shriver Z et al (2003) Rational design of low-molecular weight heparins with improved in vivo activity. Proc Natl Acad Sci USA 100:651-656. doi: 10.1073/pnas.252643299
23. Griffith MJ, Noyes CM, Church FC (1985) Reactive site peptide structural similarity between heparin cofactor II and antithrombin III. J Biol Chem 260:2218-2225
24. Davis AE 3rd, Aulak KS, Zahedi K et al (1993) C1 inhibitor. Methods Enzymol 223:97-120. doi: 10.1016/0076-6879(93)23040-T
25. Church FC, Whinna HC (1986) Rapid sulfopropyl-disk chromatographic purification of bovine and human thrombin. Anal Biochem 157:77-83. doi: 10.1016/0003-2697(86)90198-3
26. McCord DM, Monroe DM, Smith KJ et al (1990) Characterization of the functional defect in factor IX Alabama. Evidence for a conformational change due to high affinity calcium binding in the first epidermal growth factor domain. J Biol Chem 265:10250-10254
27. Oliver J, Monroe D, Roberts H et al (1999) Thrombin activates factor XI on activated platelets in the absence of factor XII. Arterioscler Thromb Vasc Biol 19:170-177
28. Hoffman M, Monroe DM, Roberts HR (1992) A rapid method to isolate platelets from human blood by density gradient centrifugation. Am J Clin Pathol 98:531-533
29. Kempton CL, Hoffman M, Roberts HR et al (2005) Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations. Arterioscler Thromb Vasc Biol 25:861-866. doi: 10.1161/ 01.ATV.0000155987.26583.9b
30. Allen GA, Wolberg AS, Oliver JA et al (2004) Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost 2:402-413. doi: 10.1111/j.1538-7933.2003.00617.x
31. Pratt CW, Monroe DM (1992) Microplate coagulation assays. Biotechniques 13:430-433
32. Rezaie A, Cooper S, Church F et al (1995) Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex. J Biol Chem 270:25336-25339. doi: 10.1074/jbc.270.43.25336
33. Preston FW (1952) The antiheparin effect of Polybrene (A polymer of N, N, N', N,-tetramethylhexamethylenediamine and trimethylene bromide). J Lab Clin Med 40:927-935
34. Leytus SP, Peltz SW, Mangel WF (1983) Adaptation of acyl-enzyme kinetic theory and an experimental method for evaluating the kinetics of fast-acting, irreversible protease inhibitors. Biochim Biophys Acta 742:409-418
35. Montalescot G, Collet JP, Tanguy ML et al (2004) Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 110:392-398. doi: 10.1161/ 01.CIR.0000136830.65073.C7
36. Rezaie AR, Olson ST (2000) Calcium enhances heparin catalysis of the antithrombin-factor Xa reaction by promoting the assembly of an intermediate heparin-antithrombin-factor Xa bridging complex. Demonstration by rapid kinetics studies. Biochemistry 39:12083-12090. doi: 10.1021/bi0011126
37. Yang L, Manithody C, Olson ST et al (2003) Contribution of basic residues of the autolysis loop to the substrate and inhibitor specificity of factor IXa. J Biol Chem 278:25032-25038. doi: 10.1074/ jbc.M302174200
38. Armstrong PW, Chang WC, Wallentin L et al (2006) Efficacy and safety of unfractionated heparin versus enoxaparin: A pooled analysis of ASSENT-3 and -3 PLUS data. CMAJ 174:1421-1426. doi: 10.1503/cmaj.051410
39. Cavusoglu E, Lakhani M, Marmur JD (2005) The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration. J Invasive Cardiol 17:416-421
40. McNeely TB, Griffith MJ (1985) The anticoagulant mechanism of action of heparin in contact-activated plasma: Inhibition of factor X activation. Blood 65:1226-1231
41. Beguin S, Dol F, Hemker HC (1991) Factor IXa inhibition contributes to the heparin effect. Thromb Haemost 66:306-309
42. Sumner WT, Monroe DM, Hoffman M (1996) Variability in platelet procoagulant activity in healthy volunteers. Thromb Res 81:533-543. doi: 10.1016/0049-3848(96)00028-X